Label: SODIUM SULFACETAMIDE 9% AND SULFUR 4% CLEANSER- sodium sulfacetamide, sulfur liquid

  • NDC Code(s): 83720-534-06, 83720-534-12, 83720-534-16
  • Packager: Oncor Pharmaceuticals
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: unapproved drug other

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated May 10, 2024

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    Sodium Sulfacetamide 9% Sulfur 4%

    Rx Only

  • DESCRIPTION

    DESCRIPTION:

    Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent.

    Chemically sodium sulfacetamide is N-[(4-aminophenyl) sulfonyl)acetamide, monosodium salt, monohydrate. The structural formula is:

    Structure

    Each gram of Sodium Sulfacetamide 9% and Sulfur 4% Cleanser contains 90 mg of sodium sulfacetamide and 40 mg of sulfur in a cleanser containing Aloe vera leaf extract, Butylated hydroxytoluene, Cetyl alcohol, Citric acid, Cocamidopropyl betaine, Disodium EDTA, Glycerin, Glyceryl
    stearate SE, PEG-100 stearate, Phenoxyethanol, Purified water, Sodium laureth sulfate, Sodium thiosulfate, Stearyl alcohol, Triacetin, Xanthan gum.

  • CLINICAL PHARMACOLOGY

    CLINICAL PHARMACOLOGY:

    Sodium sulfacetamide exerts a bacteriostatic effect against sulfonamide sensitive gram-positive and gram-negative microorganisms commonly
    isolated from secondary cutaneous pyogenic infections. It acts by restricting the synthesis of folic acid required by bacteria for growth, by its
    competition with para-aminobenzoic acid. There is no clinical data available on the degree and rate of systemic absorption of this product when applied to the skin or scalp. However, significant absorption of sodium sulfacetamide through the skin has been reported.

    The following in vitro data is available but the clinical significance is unknown. Organisms that show susceptibility to sodium sulfacetamide are:
    Streptococci, Staphylococci, E. coli, Klebsiella pneumoniae, Pseudomonas pyocyanea, Salmonella species, Proteus vulgaris, Nocardia and Actinomyces.

    The exact mode of action of sulfur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.

  • INDICATIONS & USAGE

    DIRECTIONS FOR USE:

    Wash affected area once or twice daily, or as directed by your physician. Avoid contact with eyes or mucous membranes. Wet skin and liberally apply to areas to be cleansed, massage gently into skin for 10-20 seconds working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing cleanser off sooner or using less often. See label booklet for Full prescribing Information.

    INDICATIONS:

    Sodium Sulfacetamide 9% & Sulfur 4% Cleanser is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

  • CONTRAINDICATIONS

    CONTRAINDICATIONS:

    Sodium Sulfacetamide 9% & Sulfur 4% Cleanser is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or
    any other component of this preparation. Sodium Sulfacetamide 9% & Sulfur 4% Cleanser is not to be used by patients with kidney disease.

  • WARNINGS

    WARNING

    Although it is rare, sensitivity to sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis,
    acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice, and contact dermatitis indicate hypersensitivity to sulfonamides. Particular
    caution should be employed if areas of denuded or abraded skin are involved.


    FOR EXTERNAL USE ONLY. NOT FOR INTRA VAGINAL OR OPHTHALMIC USE.
    (KEEP AWAY FROM EYES).
    KEEP OUT OF REACH OF CHILDREN.
    Shake well before use


    In case of accidental ingestion contact a Poison Control Center immediately.
    Keep container tightly closed.

  • PRECAUTIONS

    PRECAUTIONS:

    GENERAL:
    If irritation develops, use of the product should be discontinued and appropriate therapy instituted. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. The object of this therapy is to achieve desquamation without irritation, but
    sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne
    vulgaris, but patients should be cautioned about the possibility.

    INFORMATION FOR PATIENTS:
    Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. If excessive Irritation develops,
    discontinue use and consult your physician.

    CARCINOGENESIS, MUTAGENESIS AND IMPAIRMENT OF FERTILITY:
    Long-term studies in animals have not been performed to evaluate carcinogenic potential.

    PREGNANCY:
    Category C. Animal reproduction studies have not been conducted with Sodium Sulfacetamide 9% & Sulfur 4% Cleanser. It is also not known
    whether Sodium Sulfacetamide 9% & Sulfur 4% Cleanser can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Sulfacetamide 9% & Sulfur 4% Cleanser should be given to a pregnant woman only if clearly needed.

    NURSING MOTHERS:
    It is not known whether sodium sulfacetamide is excreted in the human milk following topical use of Sodium Sulfacetamide 9% & Sulfur 4%
    Cleanser. However, small amounts of orally administered sulfonamides have milk. In view of this and because many drugs are excreted in human
    milk, caution should be exercised when Sodium Sulfacetamide 9% & Sulfur 4% Cleanser is administered to a nursing woman.

    PEDIATRIC USE:
    Safety and effectiveness in children under the age of 12 have not been established.

  • ADVERSE REACTIONS

    ADVERSE REACTIONS:
    Although rare, sodium sulfacetamide may cause local irritation.

    Call your doctor for medical advice about side effects.

    CAUTION:
    If redness or irritation occurs, discontinue use.

  • DOSAGE & ADMINISTRATION

    DOSAGE AND ADMINISTRATION:
    Wash affected areas once or twice daily, or as directed by your physician. Avoid contact with eyes or mucous membranes. Wet skin and liberally
    apply to areas to be cleansed, massage gently into skin for 10-20 seconds working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing cleanser off sooner or using less often.

  • HOW SUPPLIED

    HOW SUPPLIED:
    Sodium Sulfacetamide 9% & Sulfur 4% Cleanser is available:
    6 oz (170 g) bottle, NDC 83720-534-06.
    12 oz (340 g) bottle, NDC 83720-534-12.
    16 oz (454 g) bottle, NDC 83720-534-16

  • STORAGE AND HANDLING

    STORAGE:
    Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). Brief exposure to temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25°C (77°F); however, such exposure should be minimized.

  • SPL UNCLASSIFIED SECTION

    NOTICE:
    Protect from freezing and excessive heat. The product may tend to darken slightly on storage. Slight discoloration does not impair the efficacy or safety of the product. Keep bottle tightly closed.

    Occasionally, a slight discoloration of fabric may occur when an excessive amount of the product is used and comes in contact with white fabrics. This discoloration, however, presents no problem, as it is readily removed by ordinary laundering without bleaches.

    This bottle is not filled to the top but does contain 16 oz of product as identified on the front panel of the bottle.

    In case of accidental ingestion contact a Poison Control Center immediately. Keep container tightly closed.

    You may report side effects by calling Oncor Pharmaceuticals
    (9 a.m. to 5 p.m. EST), at 1-443-876-7900 or FDA at 1-800-FDA-1088.

  • SPL UNCLASSIFIED SECTION

    Manufactured In USA For :
    ONCOR PHARMACEUTICALS
    8815 Center Park Dr Suite 430
    Columbia
    Maryland 21045
    Rev. 05/24

  • PRINCIPAL DISPLAY PANEL

    ONCOR PHARMACEUTICALS

    NDC 83720-534-16

    Sodium Sulfacetamide

    & Sulfur

    Sodium Sulfacetamide 9%

    Sulfur 4%

    9% / 4%

    Cleanser

    For External Use Only

    Rx Only

    NET WT. 16 OZ. (454 g)

    Tube

  • INGREDIENTS AND APPEARANCE
    SODIUM SULFACETAMIDE 9% AND SULFUR 4% CLEANSER 
    sodium sulfacetamide, sulfur liquid
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:83720-534
    Route of AdministrationTOPICAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    SULFACETAMIDE SODIUM (UNII: 4NRT660KJQ) (SULFACETAMIDE - UNII:4965G3J0F5) SULFACETAMIDE SODIUM90 mg  in 1 g
    SULFUR (UNII: 70FD1KFU70) (SULFUR - UNII:70FD1KFU70) SULFUR4 mg  in 1 g
    Inactive Ingredients
    Ingredient NameStrength
    PHENOXYETHANOL (UNII: HIE492ZZ3T)  
    TRIACETIN (UNII: XHX3C3X673)  
    ALOE VERA LEAF (UNII: ZY81Z83H0X)  
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    COCAMIDOPROPYL BETAINE (UNII: 5OCF3O11KX)  
    CETYL ALCOHOL (UNII: 936JST6JCN)  
    CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)  
    EDETATE DISODIUM (UNII: 7FLD91C86K)  
    GLYCERIN (UNII: PDC6A3C0OX)  
    GLYCERYL STEARATE SE (UNII: FCZ5MH785I)  
    GREEN TEA LEAF (UNII: W2ZU1RY8B0)  
    PEG-100 STEARATE (UNII: YD01N1999R)  
    WATER (UNII: 059QF0KO0R)  
    SODIUM THIOSULFATE (UNII: HX1032V43M)  
    SODIUM LAURETH SULFATE (UNII: BPV390UAP0)  
    STEARYL ALCOHOL (UNII: 2KR89I4H1Y)  
    XANTHAN GUM (UNII: TTV12P4NEE)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:83720-534-12340 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product05/10/2024
    2NDC:83720-534-16454 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product05/10/2024
    3NDC:83720-534-06170 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product05/10/2024
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    unapproved drug other05/10/2024
    Labeler - Oncor Pharmaceuticals (119032580)
    Registrant - Oncor Pharmaceuticals (119032580)